Last reviewed · How we verify
Capecitabine plus temozolomide VS Capecitabine
Capecitabine is a prodrug that is converted into 5-fluorouracil, which interferes with DNA synthesis, thereby inhibiting cancer cell growth. Temozolomide works by methylating DNA, which triggers cell death in rapidly dividing cancer cells.
Capecitabine is a prodrug that is converted into 5-fluorouracil, which interferes with DNA synthesis, thereby inhibiting cancer cell growth. Temozolomide works by methylating DNA, which triggers cell death in rapidly dividing cancer cells. Used for Advanced breast cancer, Metastatic colorectal cancer.
At a glance
| Generic name | Capecitabine plus temozolomide VS Capecitabine |
|---|---|
| Also known as | Temoram, Xeloda |
| Sponsor | Asan Medical Center |
| Drug class | Antineoplastic agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Capecitabine's mechanism of action is primarily through the inhibition of thymidylate synthase, which is necessary for DNA synthesis. This leads to the formation of DNA adducts, which prevent DNA replication and transcription. Temozolomide, on the other hand, is an alkylating agent that methylates DNA, leading to the formation of DNA adducts that trigger cell death in rapidly dividing cancer cells.
Approved indications
- Advanced breast cancer
- Metastatic colorectal cancer
Common side effects
- Hand-foot syndrome
- Diarrhea
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC (PHASE2)
- Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: